Home Cart Sign in  
Chemical Structure| 1614-73-9 Chemical Structure| 1614-73-9

Structure of 1614-73-9

Chemical Structure| 1614-73-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Lucas B. Fallot ; R. Rama Suresh ; Courtney L. Fisher ; Veronica Salmaso ; Robert D. O’Connor ; Noy Kaufman , et al.

Abstract: We previously reported 1H-imidazo[4,5-c]quinolin-4-amines as A3 adenosine receptor (A3AR) positive allosteric modulators (PAMs). A3AR agonists, but not PAMs, are in clinical trials for inflammatory diseases and liver conditions. We synthesized new analogues to distinguish 2-cyclopropyl antagonist 17 (orthosteric interaction demonstrated by binding and predicted computationally) from PAMs (derivatives with large 2-alkyl/cycloalkyl/bicycloalkyl groups). We predicted PAM binding at a hydrophobic site on the A3AR cytosolic interface. Although having low Caco-2 permeability and high plasma protein binding, hydrophobic 2-cyclohept-4-enyl-N-3,4-dichlorophenyl, MRS7788 18, and 2-heptan-4-yl-N-4-iodophenyl, MRS8054 39, derivatives were orally bioavailable in rat. 2-Heptan-4-yl-N-3,4-dichlorophenyl 14 and 2-cyclononyl-N-3,4-dichlorophenyl 20 derivatives and 39 greatly enhanced Cl-IB-MECA-stimulated [35S]GTPγS binding Emax, with only 12b trending toward decreasing the agonist EC50. A feasible route for radio-iodination at the p-position of a 4-phenylamino substituent suggests a potential radioligand for allosteric site binding. Herein, we advanced an allosteric approach to developing A3AR-activating drugs that are potentially event- and site-specific in action.

Purchased from AmBeed:

Fallot, Lucas Brett ;

Abstract: Positive allosteric modulators (PAMs) of G protein-coupled receptors (GPCRs) bind to topographically distinct sites from orthosteric agonists, causing receptor conformational changes that increase agonist affinity, potency, and/or efficacy. 1Himidazo[4,5-c]quinolin-4-amine derivatives were identified as A3 adenosine receptor (A3AR) PAMs. Here, we introduce a 6-step synthesis applied to four groups of 1Himidazo[4,5-c]quinolin-4-amine derivatives to explore structure-activity relationships and pharmacokinetics. We show the ability to fine-tune both 2-cycloalkyl and open ring derivatives as competitive antagonists and/or allosteric modulators. These activities were separated pharmacologically using chimeric mouse/human A3ARs to show the PAM binding region likely to occur at a hydrophobic site on the A3AR cytosolic interface distinct from the orthosteric site. 2-Cyclononyl-N-(3,4-dichlorophenyl) 20 (1 µM) derivative increased the A3AR agonist potency two-fold in [ 35S]GTPγS binding, as well as Emax (242%). 2-(Heptan-4-yl)-N-(3,4-dichlorophenyl) 2, 2-(hept-4-en-1-yl)-N-(3,4- viii dichlorophenyl) 10, and 2-(heptan-4-yl)-N-(4-iodophenyl) 31 (1 µM) derivatives were highly efficacious (Emax = 216%, 241% and, 223%, respectively). Although hydrophobic and having low permeability and high plasma protein binding, derivative 10 was orally bioavailable in the rat. The derivatives tested lacked high-affinity off-target binding to forty-five other membrane proteins. Furthermore, we demonstrated a route for radioiodination at the para-position of a 4-phenylamino substituent to prepare a radioligand for allosteric site binding. Herein, we advanced the allosteric approach to developing drugs for A3AR activation that are potentially event- and site-specific in action.

Purchased from AmBeed:

Alternative Products

Product Details of [ 1614-73-9 ]

CAS No. :1614-73-9
Formula : C8H12O2
M.W : 140.18
SMILES Code : O=C(C1CCC=CCC1)O
MDL No. :MFCD00021676
InChI Key :MVALBWJIVQGSGK-UHFFFAOYSA-N
Pubchem ID :292754

Safety of [ 1614-73-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1614-73-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 0
Fraction Csp3 0.62
Num. rotatable bonds 1
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 39.75
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

37.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.53
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.63
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.82
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.46
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.2
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.53

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.67
Solubility 3.0 mg/ml ; 0.0214 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.03
Solubility 1.32 mg/ml ; 0.00942 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-0.47
Solubility 47.1 mg/ml ; 0.336 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.0 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.85
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1614-73-9 ]

Alkenyls

Chemical Structure| 7686-77-3

A117980 [7686-77-3]

Cyclopent-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 2305-26-2

A214094 [2305-26-2]

(1R,2S)-rel-Cyclohex-4-ene-1,2-dicarboxylic acid

Similarity: 0.96

Chemical Structure| 5708-19-0

A269031 [5708-19-0]

(S)-Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 5709-98-8

A670232 [5709-98-8]

(R)-Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 4771-80-6

A894968 [4771-80-6]

Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Aliphatic Cyclic Hydrocarbons

Chemical Structure| 7686-77-3

A117980 [7686-77-3]

Cyclopent-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 2305-26-2

A214094 [2305-26-2]

(1R,2S)-rel-Cyclohex-4-ene-1,2-dicarboxylic acid

Similarity: 0.96

Chemical Structure| 5708-19-0

A269031 [5708-19-0]

(S)-Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 5709-98-8

A670232 [5709-98-8]

(R)-Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 4771-80-6

A894968 [4771-80-6]

Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Carboxylic Acids

Chemical Structure| 7686-77-3

A117980 [7686-77-3]

Cyclopent-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 2305-26-2

A214094 [2305-26-2]

(1R,2S)-rel-Cyclohex-4-ene-1,2-dicarboxylic acid

Similarity: 0.96

Chemical Structure| 5708-19-0

A269031 [5708-19-0]

(S)-Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 5709-98-8

A670232 [5709-98-8]

(R)-Cyclohex-3-enecarboxylic acid

Similarity: 0.96

Chemical Structure| 4771-80-6

A894968 [4771-80-6]

Cyclohex-3-enecarboxylic acid

Similarity: 0.96